natalizumab
biogen
['natalizumab', 'advance']
late breaking #ectrims2022: among patients with progressive #ms, advanced disability &amp; low pretreatment relapse activity, +patients with recent disability progression, #ahsct is not superior in reducing disability progression or allowing reduction of disability than natalizumab. 
Peer-reviewed. Multidisciplinary. Open access.
International Journal of MS Care: Consortium of Multiple Sclerosis Centers' official journal. (ISSN: 1537-2073)